Topic: drug manufacturing
With plans for further expansion in China, Japan’s Eisai has opened a new solid dose plant in Suzhou.
Athenex is moving forward with a project to build a $210 million manufacturing plant in New York that will be financed primarily by the state.
Teva has worked out agreements with workers to close another plant in Israel. That is two down and about 40 to go.
Sun Pharmaceuticals has increased its ownership in its Malaysia production venture twice in three months and now holds an 85.9% share.
Legend teams with J&J on CAR-T project, Eisai and Biogen's Alzheimer's drug fails in early readout, Impax and Bora Pharma ink deal.
BMS forms new I-O deal with Ono, Eisai's Lenvima wins NICE nod in kidney cancer, Sanofi tries to dig out of Philippines Dengvaxia fallout.
Contractor ADC Biotechnology is moving quickly to get a manufacturing facility built in Wales to produce its new ADCs.
Russian biotech Biocad said it reached a deal with Sothema Labs of Morocco to produce biosimilars rituximab and bevacizumab, used to treat cancer.
As Emergent BioSolutions pushes toward its goal of reaching $1 billion in annual revenues, the company has secured an important regulatory milestone.
Biocon has resolved FDA concerns about a plant in India, setting it and Mylan up to potentially win FDA approval for the first Herceptin biosimilar.